Inventor · disambiguated record
J. Yun Tso
Also filed as: TSO J JUN · TSO J Y · TSO J YUN · TSO YUN J
49 granted patents·18 pending applications·2,658 citations·filing 1987–2024
99Inventor score
Files withJN BIOSCIENCES LLC12ABBVIE BIOTHERAPEUTICS INC11PROTEIN DESIGN LABS INC9WILLIAMS MARNA6UNIV TEXAS5
Top patents by PatentIndex Score
67 records- 0199US7217797B2Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesisPDL BIOPHARMA INC·Filed 2003·Granted May 15, 2007·298 cites·50 claims
- 0298US5777085AHumanized antibodies reactive with GPIIB/IIIAPROTEIN DESIGN LABS INC·Filed 1995·Granted Jul 7, 1998·274 cites·17 claims
- 0397US9382319B2Hybrid constant regionsJN BIOSCIENCES LLC·Filed 2014·Granted Jul 5, 2016·33 cites·23 claims
- 0497US9163085B2Anti-OX40 antibodies and methods of treating cancerLIU YONG-JUN·Filed 2012·Granted Oct 20, 2015·94 cites·7 claims
- 0597US9006399B2Anti-OX40 antibodies and methods of using the sameLIU YONG-JUN·Filed 2011·Granted Apr 14, 2015·114 cites·9 claims
- 0697US8008450B2Therapeutic use of anti-CS1 antibodiesABBOTT BIOTHERAPEUTICS CORP·Filed 2009·Granted Aug 30, 2011·64 cites·4 claims
- 0797US7361740B2Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesisPDL BIOPHARMA INC·Filed 2004·Granted Apr 22, 2008·92 cites·16 claims
- 0896US10053517B2Hybrid constant regionsJN BIOSCIENCES LLC·Filed 2016·Granted Aug 21, 2018·11 cites·21 claims
- 0996US9540442B2Antibodies or fusion proteins multimerized via cysteine mutation and a mu tailpieceJN BIOSCIENCES LLC·Filed 2013·Granted Jan 10, 2017·27 cites·21 claims
- 1096US7365168B2Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesisPDL BIOPHARMA INC·Filed 2005·Granted Apr 29, 2008·38 cites·8 claims
- 1196US5834597AMutated nonactivating IgG2 domains and anti CD3 antibodies incorporating the samePROTEIN DESIGN LABS INC·Filed 1996·Granted Nov 10, 1998·499 cites·18 claims
- 1294US5932448ABispecific antibody heterodimersPROTEIN DESIGN LABS INC·Filed 1991·Granted Aug 3, 1999·576 cites·16 claims
- 1393US9527917B2Nucleic acid encoding anti-OX40 antibodiesUNIV TEXAS·Filed 2015·Granted Dec 27, 2016·12 cites·17 claims
- 1493US7709610B2Therapeutic use of anti-CS1 antibodiesFACET BIOTECH CORP·Filed 2004·Granted May 4, 2010·40 cites·26 claims
- 1593US7381803B1Humanized antibodies against CD3PDL BIOPHARMA INC·Filed 2000·Granted Jun 3, 2008·74 cites·9 claims
- 1692US10537633B2Antibodies to TIGITJN BIOSCIENCES LLC·Filed 2017·Granted Jan 21, 2020·13 cites·9 claims
- 1792US9695246B2Anti-OX40 antibodies and methods of using the sameUNIV TEXAS·Filed 2015·Granted Jul 4, 2017·10 cites·9 claims
- 1892US6129914ABispecific antibody effective to treat B-cell lymphoma and cell linePROTEIN DESIGN LABS INC·Filed 1995·Granted Oct 10, 2000·195 cites·28 claims
- 1991US9028830B2Antibodies to CD122TSO J YUN·Filed 2011·Granted May 12, 2015·21 cites·13 claims
- 2090US10851173B2Anti-OX40 antibodies and methods of using the sameUNIV TEXAS·Filed 2018·Granted Dec 1, 2020·3 cites·12 claims
- 2190US8461306B2Therapeutic use of anti-CS1 antibodiesWILLIAMS MARNA·Filed 2011·Granted Jun 11, 2013·10 cites·19 claims
- 2289US9260528B2DAC HYP compositions and methodsABBVIE BIOTHERAPEUTICS INC·Filed 2015·Granted Feb 16, 2016·7 cites·8 claims
- 2388US10053720B2Vectors and host cells comprising a modified SV40 promoter for protein expressionABBVIE BIOTHERAPEUTICS INC·Filed 2016·Granted Aug 21, 2018·5 cites·19 claims
- 2488US9676860B2DAC HYP compositions and methodsABBVIE BIOTHERAPEUTICS INC·Filed 2015·Granted Jun 13, 2017·7 cites·8 claims
- 2588US8445646B2Therapeutic use of anti-CS1 antibodiesWILLIAMS MARNA·Filed 2011·Granted May 21, 2013·8 cites·16 claims
- 2688US8444980B2Therapeutic use of anti-CS1 antibodiesWILLIAMS MARNA·Filed 2011·Granted May 21, 2013·8 cites·40 claims
- 2788US8349330B2Therapeutic use of anti-CS1 antibodiesABBOTT BIOTHERAPEUTICS CORP·Filed 2011·Granted Jan 8, 2013·8 cites·16 claims
- 2888US8088898B2Therapeutic use of anti-CS1 antibodiesWILLIAMS MARNA·Filed 2009·Granted Jan 3, 2012·7 cites·9 claims
- 2987US9815903B2DAC HYP compositionsABBVIE BIOTHERAPEUTICS INC·Filed 2017·Granted Nov 14, 2017·5 cites·12 claims
- 3087US9340619B2DAC HYP compositions and methodsABBVIE BIOTHERAPEUTICS INC·Filed 2015·Granted May 17, 2016·6 cites·4 claims
- 3187US8436146B2Therapeutic use of anti-CS1 antibodiesWILLIAMS MARNA·Filed 2011·Granted May 7, 2013·7 cites·18 claims
- 3287US8133981B2Therapeutic use of anti-CS1 antibodiesWILLIAMS MARNA·Filed 2009·Granted Mar 13, 2012·6 cites·16 claims
- 3385US8952134B2Hybrid constant regionsTSO J YUN·Filed 2012·Granted Feb 10, 2015·8 cites·28 claims
- 3482US5004692ACloning and expression of phosopholipase C genesPROTEIN DESIGN LABS INC·Filed 1987·Granted Apr 2, 1991·43 cites·18 claims
- 3581US11332532B2Bispecific antibodies which bind PD-L1 and GITRJN BIOSCIENCES LLC·Filed 2019·Granted May 17, 2022·1 cites·17 claims
- 3680US8821863B2Humanized anti-α 9 integrin antibodies and the uses thereofKUMAR SHANKAR·Filed 2009·Granted Sep 2, 2014·4 cites·2 claims
- 3780US8017118B2Anti-hDlk-1 antibody having an antitumor activity in vivoLIVTECH INC & MDASH TEIKYO UNIVERSITY BIOTECHNOLOGY RES CT·Filed 2009·Granted Sep 13, 2011·6 cites·8 claims
- 3879US9175081B2Therapeutic use of anti-CS1 antibodiesABBVIE BIOTHERAPEUTICS INC·Filed 2013·Granted Nov 3, 2015·2 cites·36 claims
- 3978US7888485B2Anti-pleiotrophin antibodies and methods of use thereofUNIV GEORGETOWN·Filed 2004·Granted Feb 15, 2011·7 cites·8 claims
- 4077US2024317870A1Bifunctional molecules for treatment of immune disordersJN BIOSCIENCES LLC·Filed 2024·Application pending·0 cites
- 4176US2024115696A1Antibodies to tigitJN BIOSCIENCES LLC·Filed 2023·Application pending·0 cites
- 4274US11993657B2Bifunctional molecules for treatment of immune disordersJN BIOSCIENCES LLC·Filed 2022·Granted May 28, 2024·0 cites·25 claims
- 4373US8969539B2Expression vectorsTSURUSHITA NAOYA·Filed 2009·Granted Mar 3, 2015·2 cites·8 claims
- 4471US11723971B2Antibodies to TIGITJN BIOSCIENCES LLC·Filed 2019·Granted Aug 15, 2023·0 cites·13 claims
- 4570US6894149B2Anti-HLA-DA antibodies and the methods of using thereofPROTEIN DESIGN LABS INC·Filed 2002·Granted May 17, 2005·13 cites·13 claims
- 4669US12492231B2Multimeric hybrid Fc proteins for replacement of IVIGJN BIOSCIENCES LLC·Filed 2019·Granted Dec 9, 2025·0 cites·11 claims
- 4769US2020157230A1Dac hyp compositions and methodsABBVIE BIOTHERAPEUTICS INC·Filed 2020·Application pending·0 cites
- 4869US2020031929A1Therapeutic use of anti-cs1 antibodiesABBVIE BIOTHERAPEUTICS INC·Filed 2019·Application pending·0 cites
- 4969US2022251214A1Bispecific Antibodies for Activation of Immune CellsJN BIOSCIENCES LLC·Filed 2022·Application pending·0 cites
- 5064US10196450B2Anti-OX40 antibodies and methods of using the sameUNIV TEXAS·Filed 2017·Granted Feb 5, 2019·0 cites·11 claims
Showing the top 50 of 67 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when J. Yun Tso files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →